These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32810412)

  • 41. Evaluating FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis.
    Bouzek DC; Ren CL; Thompson M; Slaven JE; Sanders DB
    Pediatr Pulmonol; 2022 Jul; 57(7):1709-1716. PubMed ID: 35429154
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
    Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
    Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
    Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
    J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spectrum Of Pulmonary Exacerbation In Children And Adolescent With Cystic Fibrosis And Physicians' Practices: Experience From Tertiary Care Center From Lower-Middle Income Country.
    Aziz DA; Shahid S; Alam A; Aziz N; Iftikhar H; Mir F
    J Ayub Med Coll Abbottabad; 2021; 33(3):363-367. PubMed ID: 34487639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
    Heltshe SL; Russell R; VanDevanter DR; Sanders DB
    J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic Fibrosis.
    Tarique AA; Tuladhar N; Kelk D; Begum N; Lucas RM; Luo L; Stow JL; Wainwright CE; Bell SC; Sly PD; Fantino E
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
    Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
    Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.
    VanDevanter DR; Heltshe SL; Hilliard JB; Konstan MW
    J Cyst Fibros; 2021 Mar; 20(2):257-263. PubMed ID: 32505525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study.
    Somayaji R; Goss CH; Khan U; Neradilek M; Neuzil KM; Ortiz JR
    Clin Infect Dis; 2017 Jun; 64(12):1760-1767. PubMed ID: 28329304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.
    VanDevanter DR; Morris NJ; Konstan MW
    J Cyst Fibros; 2016 May; 15(3):372-9. PubMed ID: 26603642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
    Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
    J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers.
    Hoppe JE; Hinds DM; Colborg A; Wagner BD; Morgan WJ; Rosenfeld M; Zemanick ET; Sanders DB
    Pediatr Pulmonol; 2020 Dec; 55(12):3400-3406. PubMed ID: 32970375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease.
    Abotsi RE; Dube FS; Rehman AM; Claassen-Weitz S; Xia Y; Simms V; Mwaikono KS; Gardner-Lubbe S; McHugh G; Ngwira LG; Kwambana-Adams B; Heyderman RS; Odland JØ; Ferrand RA; Nicol MP;
    Microbiome; 2023 Feb; 11(1):29. PubMed ID: 36803868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
    Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
    J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline.
    Aquino CSB; Rodrigues JC; Silva-Filho LVRFD
    J Bras Pneumol; 2022; 48(3):e20210237. PubMed ID: 35674545
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Defining a pulmonary exacerbation in cystic fibrosis.
    Rosenfeld M; Emerson J; Williams-Warren J; Pepe M; Smith A; Montgomery AB; Ramsey B
    J Pediatr; 2001 Sep; 139(3):359-65. PubMed ID: 11562614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
    Nichols DP; Happoldt CL; Bratcher PE; Caceres SM; Chmiel JF; Malcolm KC; Saavedra MT; Saiman L; Taylor-Cousar JL; Nick JA
    J Cyst Fibros; 2017 May; 16(3):358-366. PubMed ID: 28025037
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.
    Skolnik K; Nguyen A; Somayaji R; Thornton CS; Waddell B; Surette MG; Rabin HR; Parkins MD
    BMC Pulm Med; 2015 Dec; 15():161. PubMed ID: 26651825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
    Wilms EB; Touw DJ; Heijerman HG
    Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.